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IMPACT OF PRODUCT LIABILITY ISSUES ON INNOVATION
Session Chair - J. Michael Robinson
Canadian Speaker - Bruce A. Thomas, QC
United States Speaker - Michael J. Wagner
INTRODUCTION
J. Michael Robinson
Mr. Wagner from Baker McKenzie Litigation Group has been detained
somewhere, but he doesn't appear to be here; if he does arrive for the 3:30
time slot, we will, of course, dearly welcome him. He is the U.S. representative on this issue. I am a Canadian, and as you can see, Bruce Thomas beside
me is a Canadian, so we will have to wing it as to the U.S. input, but we
think we will be able to get that from all the lawyers in the group here, and
we can get a lively dialogue going.
As you can see this session, as Bruce observed, a very tough time slot,
Saturday afternoon when the sun is out, is on the impact of product liability
issues on innovation. There should be lots of argumentative issues coming up
there. I don't know why Henry chose me to preside over this one because I
am a solicitor, not a barrister, in Canada. We are still technically barristerssolicitors, notaries public, and commissioners for the taking of oaths and
affidavits. Does that sound fancy?
And sometimes we are even Queen's Counsel (QC), which Bruce is. I
would like to take this opportunity to point out that Ian Holloway, Dean of
the Western Law School, was just given one of these QCs by his home province of New Brunswick, and it was a truly earned QC for merit and for all the
good work that he has done. These QCs that Bruce and I have are kind of
legacies left over from the days before the province of Ontario stopped giving them out on the basis they felt there was too much politics involved.
However, the proper name for a Queen's Counsel is One of Her Majesty's
Counsel Learned in the Law. So you have the benefit of a very learned barrister here, not a solicitor.
Bruce practices at Cassels, Brock & Blackwell, Larry Herman's firm. I see
Larry has gone out to take advantage of the sun; he has probably heard your
speech before.
As a partner, Bruce looks after many corporations, domestic and foreign,
in litigation matters. He is a pure litigator. A barrister does all kinds of actions, defends class actions and international and multidistrict litigation,
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commercial and product liability claims being one of his claims of specialty,
and that's why he is particularly appropriate for this.
As I said, I am a solicitor. I am not sure where the courthouse is except
that it is across the road from my club where I take lunch and play squash. I
never go inside, and I certainly never sue anybody. But I have done work for
health and biotech companies working with universities and research foundations, and certainly can appreciate the legal liability issues arising out of
medical research, particularly in innovation - I know they are horrendous.
Bruce has a very interesting case study. Copies of it were in your handout
to illustrate the facts of a situation that gives rise to a current very substantial
wide ranging and nasty claim for tort liability against medical researchers.
Our U.S. speaker, apparently being from Illinois, was going to tell us
about a new statute there that may cap, or limit in some way, liabilities in tort
for medical research. We were very excited to learn about it, but somebody
in the audience may be able to tell us about it if our speaker doesn't appear.
Bruce also spoke when we were out in the motel where Henry used to
stick us so that we couldn't go to the baseball games or over to Severance
Hall to listen to a concert or anywhere else. Between now and then, things
have changed a great deal because I remember Bruce explaining to everybody that we don't have contingent fees or class actions in Canada, and so
your litigation risks are much lower. Well, now we do have class actions, and
we do have contingent fees. In the usual Canadian way, they are all hemmed
around by regulations and limitations and requirements for Court approval,
and they are not nearly so wild and free booting as those rights.1
Oh, I think he just came in the door. Perfect timing.
(At this point, Michael Wagner enters the conference room, and the following discussion was held:)
MR. WAGNER: I was going to say.
DR. KING: This is Michael Wagner, right?
MR. WAGNER: Right.
MR. ROBINSON: Excellent. So we don't have to make it up about this
new Illinois statute. You are going to tell us about it.
MR. WAGNER: I will make it up instead.
MR. ROBINSON: So now things have changed a great deal, and if Bruce
doesn't cover this, I am going to ask him about it anyway: Will contingent
fees and class actions have an effect in this area of product liability, particularly researchers and others? I don't think they have yet, but that will be one
of the things Bruce will deal with, and that will be a change in the whole

1 See Paul J. Martin, The Developing Role of Class Actions in Canadian Civil Justice
Reform, METROPOLITAN CORPORATE COUNSEL, November 2000 (discussing many recent laws
concerning class actions in Canada).
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litigation climate in Canada, which has grown significantly, since you spoke
last time.
So I'm going to introduce Michael from Michael Wagner's bio notes here
so we don't have to pause and break the flow later. He is with the Baker
McKenzie litigation practice in Chicago, right?
MR. WAGNER: That's right.
MR. ROBINSON: Where he represents multinational companies as well
and is a specialist in defense of class actions, multidistrict litigation, and
commercial and product liability claims. Rather than spell out all these litigation successes, we will just let him describe it.
Bruce, I think you want to go first, correct?
CANADIAN SPEAKER
(Mr. Thomas has submitted a paper which is published below in its entirety.)
MEDICAL RESEARCHERS ARE ENTITLED TO PROTECTION
FROM SUIT BY LEGISLATION IN BOTH THE DOMINION OF
CANADA AND THE UNITED STATES OF AMERICA
Bruce A. Thomas, QC*

INTRODUCTION
This paper reviews the facts of a legal case that was commenced in Ontario against an American doctor, Dr. MS. Dr. MS was sued in her former
capacity as Chair of an important international research group. The paper
reviews the nature of the claim against Dr. MS, the duty of care owed by
researchers and the potential effects of litigation on research. Ultimately, the
author opines that there is no duty of care owed by researchers in this type of
situation. However, unless legislation is put in place to prevent these types of
. Bruce A. Thomas is a Partner at Cassels Brock & Blackwell LLP. In recent years, his
primary emphasis has been on corporate and commercial related litigation. He has considerable experience in both litigating and arbitrating insurance and reinsurance coverage issues.
Bruce Thomas was appointed a Queen's Counsel in 1978. He is ranked a leading practitioner

in commercial insurance litigation in Canada by LEXPERT/American Lawyer 500 and as one
of the World's Leading Insurance & Reinsurance Lawyers by the International Financial Law

Review. He has also been named to the International Who's Who of Product Liability Defence
Lawyers.

